Solenic Medical

Solenic Medical is developing a non-invasive treatment for infections on metallic medical implants, such as those used in knee and hip replacements. The core of their business is a proprietary, patent-pending technology that utilizes alternating magnetic fields (AMF) to eradicate bacterial biofilm from the surface of these implants. This is a critical issue as biofilm shields bacteria, making them resistant to antibiotics and the body's immune response. The company's system, the Sola2 AMF Knee System, generates a controlled thermal dose by creating eddy currents on the implant's surface, which heats it enough to disrupt the biofilm without harming surrounding tissue. This approach is designed to be used in conjunction with antibiotics, enhancing their effectiveness. The market for this technology is substantial, with millions of joint replacement surgeries performed annually in the U.S., a number projected to grow significantly. The company is initially targeting the metallic components of knee implants and plans to expand to other areas like hips, elbows, and trauma-related implants.

The company's business model revolves around the commercialization of this medical device. Revenue will likely be generated from the sale of the Sola2 system to hospitals and surgical centers where revision surgeries for PJIs are performed. Solenic Medical has achieved several key milestones, including receiving an FDA Breakthrough Device designation in July 2020, which provides for priority review. The company has also secured significant funding, including a $5.1 million Series A round in June 2023, led by Johnson & Johnson Innovation – JJDC, Inc. They have completed preclinical studies in animals and successfully treated the first patient in an early feasibility human clinical trial in March 2025, a crucial step toward regulatory approval and market launch.